SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 620
Posts 92,644
Boards Moderated 29
Alias Born 09/05/02
160x600 placeholder
U.S. Stocks Close Higher On Back Of Tech, Bank Rally
Blue chips gain 200 points, new-home sales surge in April U.S. stocks surged to close higher Tuesday as a rally in financial and technology...
Top Equities Stories Of The Day
Monsanto Rejects Bayer Merger Offer, Says It's Open to Talks--2nd Update
Facebook Shifts Topics Feature Amid Bias Fears--update
GE Sets $1 Billion in Saudi Projects -- WSJ
Court Tosses Crisis-Era Fraud Fine -- WSJ
Comcast Sued by Viamedia for Monopolization of 'Spot' Cable Ad Sales Market
J.P. Morgan Private Bank Lays Off Nearly 100 Employees
Nokia to Return to Cellphones Via Licensing Pact -- Update
Toyota and Uber Reach Investment, Lease Partnership
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 201574 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist